New Patient-Centered CRO Launches with Industry Veteran Leadership

LyfeSci Research & Innovation, a new contract research organization (CRO) with a patient-centered focus, has officially launched in the Chicago area. Founded by experienced psychiatrist Dr. Tapan Parikh, the company aims to revolutionize clinical research by prioritizing patient needs and leveraging scientific expertise and technology capabilities.

Comprehensive Service Offerings

LyfeSci Research & Innovation offers a wide range of services, including:

• Preclinical studies
• Investigational new drug application preparation
• Clinical trial management
• Biostatistics
• Pharmacovigilance
• Real-world data analysis

Dr. Parikh, the founder and CEO, emphasized the company's mission, stating, "Our goal is to revolutionize the clinical research experience by placing patients at the heart of everything we do. By delivering value that reflects site needs—which in turn address patient priorities and clinical realities—we aim to improve study timelines and elevate the quality of research outcomes."

Leadership with Extensive Industry Experience

The leadership team at LyfeSci brings significant expertise to the table. Dr. Parikh, a board-certified adult and child psychiatrist, boasts a 15-year research career spanning cardiology, oncology, neuroscience, and public health. His academic background includes a medical degree from Pramukh Swami Medical College in Gujarat, India, followed by a psychiatric residency at Cooper University Hospital and a child psychiatry fellowship at Ann & Robert H. Lurie Children's Hospital of Chicago.

Joining Dr. Parikh is Dr. William Gannon Jr., who serves as LyfeSci's chief medical officer. Dr. Gannon's impressive career includes senior leadership roles at major CROs such as Quintiles (now IQVIA) and Pharmaceutical Product Development (PPD), which was acquired by Thermo Fisher Scientific for $17.4 billion in 2021.

Dr. Gannon highlighted the company's approach, saying, "By evaluating new therapies through a real-world clinical lens, we design studies that truly matter to both patients and healthcare providers. Our mission is to ensure clinical trials are accessible, practical for sites, valuable for sponsors, and ultimately transformative for patients."